Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 2, 2013, Pages 511-521

  Shibui, Soichiro ^a   Narita, Yoshitaka ^a   Mizusawa, Junki ^b   Beppu, Takaaki ^c   Ogasawara, Kuniaki ^c   Sawamura, Yutaka ^d   Kobayashi, Hiroyuki ^d   Nishikawa, Ryo ^e   Mishima, Kazuhiko ^e   Muragaki, Yoshihiro ^f   Maruyama, Takashi ^f   Kuratsu, Junichi ^g   Nakamura, Hideo ^g   Kochi, Masato ^g   Minamida, Yoshio ^h   Yamaki, Toshiaki ^h   Kumabe, Toshihiro ⁱ   Tominaga, Teiji ⁱ   Kayama, Takamasa ^j   Sakurada, Kaori ^j   Nagane, Motoo ^k   Kobayashi, Keiichi ^k   Nakamura, Hirohiko ^l   Ito, Tamio ^l   Yazaki, Takahito ^m   Sasaki, Hikaru ^m   Tanaka, Katsuyuki ⁿ   Takahashi, Hideaki ^o   Asai, Akio ^p   Todo, Tomoki ^q   Wakabayashi, Toshihiko ^r   Takahashi, Jun ^s   Takano, Shingo ^t   Fujimaki, Takamitsu ^u   Sumi, Minako ^a   Miyakita, Yasuji ^a   Nakazato, Yoichi ^v   Sato, Akihiro ^b   Fukuda, Haruhiko ^b   Nomura, Kazuhiro ^a   more..

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g KUMAMOTO UNIVERSITY   (Japan)

^h SAPPORO MEDICAL UNIVERSITY   (Japan)

ⁱ TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j YAMAGATA UNIVERSITY   (Japan)

^k KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l Nakamura Memorial Hospital   (Japan)

^m KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o NIIGATA UNIVERSITY   (Japan)

^p SAITAMA MEDICAL CENTER   (Japan)

^q UNIVERSITY OF TOKYO   (Japan)

^r NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^s KYOTO UNIVERSITY   (Japan)

^t UNIVERSITY OF TSUKUBA   (Japan)

^u TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^v GUNMA UNIVERSITY   (Japan)

more..

Author keywords

ACNU; Anaplastic astrocytoma; Glioblastoma; MGMT; Nimustine; Procarbazine

Indexed keywords

NIMUSTINE; PROCARBAZINE; TEMOZOLOMIDE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BRAIN INFARCTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HERPES ZOSTER; HUMAN; HYPOKALEMIA; HYPONATREMIA; INVOLUNTARY MOVEMENT; JAPAN; LEUKOPENIA; LIVER DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SEIZURE; SEPSIS; SIDE EFFECT; SKIN DISEASE; SPEECH DISORDER; THROMBOCYTOPENIA; THRUSH; TREMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NIMUSTINE; PROCARBAZINE;

EID: 84874109589     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2041-5     Document Type: Article

References (28)

1. The Committee of Brain Tumor Registry of Japan (2003) Report of brain tumor registry of japan (1984-2000) 12th edition. Neurol Med Chir (Tokyo) 49(Suppl):1-101
2. Glioma Meta-analysis Trialists (GMT) Group (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311):1011-1018. doi: 10.1016/S0140-6736(02)08091-1
3. Matsutani M, Nakamura O, Nakamura M, Nagashima T, Asai A, Fujimaki T, Tanaka H, Ueki K, Tanaka Y (1994) Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults. J Neurooncol 19(3):227-237
4. Wolff JE, Berrak S, Koontz Webb SE, Zhang M (2008) Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol 88(1):57-63. doi: 10.1007/s11060-008-9533-5
5. Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K, Yamamoto S, Kageyama N, Handa H, Mogami H et al (1986) Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg 64(1):53-57. doi: 10.3171/jns.1986.64.1.0053
6. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50(19):6119-6129
7. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 58(5):1068-1073
8. 6-alkylguanine-DNA alkyltransferase in rat tissues. Carcinogenesis 15(8):1681-1688
9. 6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair. Cancer Res 50(9):2759-2764
10. Wedge SR, Porteus JK, May BL, Newlands ES (1996) Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br J Cancer 73(4):482-490
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
12. Bernstein D, Lagakos SW (1978) Sample size and power determination for stratified clinical trials. J Stat Comput Simul 8:65-73
13. 6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 2(4):735-741
14. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350-1354. doi: 10.1056/NEJM200011093431901
15. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003. doi: 10.1056/NEJMoa043331
16. Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T (2010) O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 15(4):352-358. doi: 10.1007/s10147-010-0065-6
17. van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Idbaih A, Sanson M, Smitt PA, French PJ (2011) A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res 17(22):7148-7155. doi: 10.1158/1078-0432.CCR-11-1274
18. Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M (2010) O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol 12(3):283-288. doi: 10.1093/neuonc/nop050
19. Okita Y, Narita Y, Miyakita Y, Ohno M, Fukushima S, Kayama T, Shibui S (2012) Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol. doi: 10.1007/s10014-012-0084-2
20. Aldape KD, Wang M, Sulman EP, Hegi M, Colman H, Jones G, Chakravarti A, Mehta MP, Andrews DW, Long L, Diefes K, Heathcock L, Jenkins R, Schultz CJ, Gilbert MR, Group RTO (2011) RTOG 0525: Molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma. ASCO Annu Meet Proc 29(18-suppl):LBA2000
21. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25(22):3357-3361. doi: 10.1200/JCO.2007.10.7722
22. 6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27(8):1262-1267. doi: 10.1200/JCO.2008.18.8417
23. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS (2002) Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20(9):2277-2283
24. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
25. Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, Franceschi E (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 10(3):361-367. doi: 10.1215/15228517-2008-008
26. van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 120(3):297-304. doi: 10.1007/s00401-010-0725-7
27. Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ (2008) Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer 44(9):1210-1216. doi: 10.1016/j.ejca.2007.12.005
28. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79(7):1381-1393